Filing Analysis
Actuate Therapeutics received a notice from Nasdaq stating that its Market Value of Listed Securities (MVLS) fell below the $50 million minimum requirement between June 1, 2026, and July 14, 2026. The company has been granted a 180-day compliance period ending January 11, 2027, to regain compliance.
🚩 Red Flags
- Failure to meet minimum market value requirements (MVLS < $50M).
- Risk of delisting from the Nasdaq Global Market if compliance is not met by January 11, 2027.
- Potential for transfer to the less liquid Nasdaq Capital Market.
📋 Key Facts
- Nasdaq notified the company on July 15, 2026, regarding non-compliance with MVLS requirements.
- The deficiency period cited is June 1, 2026, through July 14, 2026.
- Compliance deadline (Compliance Date) is January 11, 2027.
- To regain compliance, the company must maintain an MVLS of $50 million or more for at least ten consecutive business days during the compliance period.
- The company's stock continues to trade on the Nasdaq Global Market under symbol 'ACTU'.
Actuate Therapeutics, Inc. reported the voting results from its virtual Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected two Class II directors to serve three-year terms and ratified the appointment of Crowe LLP as the company's independent registered public accounting firm for 2026.
📋 Key Facts
- The Annual Meeting of Stockholders was held virtually on May 21, 2026.
- Stockholders elected Aaron G.L. Fletcher, Ph.D. (14,877,247 votes For) and Jason Keyes (16,727,875 votes For) as Class II directors to serve until the 2029 Annual Meeting.
- Stockholders ratified the appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 18,571,817 votes For, 50,023 votes Against, and 9,741 abstentions.
Actuate Therapeutics announced FDA clearance of an Investigational New Drug (IND) application for its lead candidate, elraglusib, to proceed with a Phase 1/2 study. The company also released an updated corporate presentation outlining its future development plans.
📋 Key Facts
- FDA cleared the IND application for elraglusib on May 11, 2026.
- The clearance allows the company to initiate a Phase 1/2 clinical study.
- The company furnished a new corporate presentation as Exhibit 99.2.
- Actuate Therapeutics is an emerging growth company listed on the Nasdaq Stock Market.
Actuate Therapeutics expanded its board to eight members and appointed Dr. Martin H. Huber, a veteran oncology executive, as a Class III director. Dr. Huber will also provide research and development advisory services under a separate consulting agreement.
🚩 Red Flags
- Potential related-party conflict: The director is receiving additional consulting fees ($12,000/year) beyond standard board compensation.
📋 Key Facts
- Appointed Martin H. Huber, MD, to the Board of Directors effective May 1, 2026.
- Board expanded from seven to eight members to accommodate the new appointment.
- Dr. Huber will receive an annual retainer of $44,000 and an initial grant of 30,000 stock options vesting over three years.
- Entered into a consulting agreement with Dr. Huber for R&D advisory services at $3,000 per quarter.
- Dr. Huber previously served as CEO of Mersana Therapeutics and CMO of TESARO (acquired by GSK).
Actuate Therapeutics, Inc. issued a press release regarding updated clinical trial data for its elraglusib combination therapy in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The announcement pertains to the Actuate-1801 Part 3B Phase 2 trial.
📋 Key Facts
- Company released updated data from the ongoing, fully enrolled randomized Phase 2 trial of elraglusib + gemcitabine/nab-paclitaxel (GnP).
- The study focuses on first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
- The filing is under Item 7.01 (Regulation FD Disclosure) and the information is furnished, not filed.
Actuate Therapeutics, Inc. has entered into an 'at the market' (ATM) issuance sales agreement to facilitate the potential sale of up to $100 million in common stock through B. Riley Securities and Craig-Hallum Capital Group LLC.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $100M ATM program.
- ATM offerings are often used by micro-cap biotech companies to fund ongoing operations/burn rate, signaling a need for immediate liquidity.
📋 Key Facts
- Entered into At the Market Issuance Sales Agreement on November 28, 2025.
- Aggregate offering price capacity: up to $100,000,000.
- Sales Agents: B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC.
- Commission rate: Up to 3.0% of gross sales proceeds.
- The offering will be conducted under an existing Form S-3 registration statement (File No. 333-289988) filed on September 2, 2025.
Actuate Therapeutics, Inc. filed an 8-K under Item 8.01 (Other Information) to provide disclosure channels for disseminating material information to the public.
📋 Key Facts
- The filing is dated November 21, 2025.
- The company utilizes its website, press releases, SEC filings, and social media to communicate material developments.
- Registrant is an emerging growth company.
Actuate Therapeutics, Inc. has entered into an underwriting agreement with Lucid Capital Markets, LLC for a public offering of 2,142,858 shares of common stock at $7.00 per share. The offering is expected to raise approximately $15 million in gross proceeds and is slated to close on September 11, 2025.
🚩 Red Flags
- Dilution risk for existing shareholders due to the issuance of new common stock.
📋 Key Facts
- Offering size: 2,142,858 shares of common stock plus a 30-day over-allotment option for an additional 321,428 shares.
- Offering price: $7.00 per share.
- Estimated gross proceeds: $15.0 million (before discounts and expenses).
- Underwriter: Lucid Capital Markets, LLC.
- Lock-up period: Directors and executive officers are prohibited from selling securities until December 9, 2025.
- Expected closing date: September 11, 2025.
Actuate Therapeutics entered into a securities purchase agreement for a private placement of common stock and warrants to raise approximately $4.7 million in gross proceeds. The offering includes registration rights with liquidated damages provisions and involves a significant related party.
🚩 Red Flags
- Potential dilution via warrants and subsequent registration of shares.
- Liquidated damages clauses in the Registration Rights Agreement increase financial/operational risk.
- Related-party involvement: Bios 2024 Co-Invest, LP (controlled by Company Chairman Dr. Aaron G.L. Fletcher) is a purchaser and will own ~49.9% of the company post-closing.
- Forward-looking statements explicitly mention 'substantial doubt as to our ability to continue as a going concern'.
📋 Key Facts
- Private placement of 666,497 shares of common stock at $7.00 per share.
- Issuance of warrants to purchase up to 666,497 additional shares at an exercise price of $7.00.
- Total anticipated gross proceeds: approximately $4.7 million.
- Warrants expire 20 days after a 'Milestone Date' (FDA Breakthrough Therapy designation for elraglusib or FDA determination on Phase 2/3 data usage).
- Registration Rights Agreement requires filing a registration statement by August 9, 2025.
- Includes liquidated damages provisions in the event of registration failures.
Actuate Therapeutics hosted a Key Opinion Leader (KOL) event to review topline Phase 2 data for elraglusib in combination with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer. While the filing focuses on clinical data presentation, it contains explicit forward-looking language regarding significant doubt about the company's ability to continue as a going concern.
🚩 Red Flags
- Going concern warning: The filing states 'our financial condition raises substantial doubt as to our ability to continue as a going concern'.
- Liquidity risk: Explicitly mentions the requirement for additional capital beyond Q2 2025.
- Clinical/Regulatory risk: High uncertainty regarding elraglusib's potential side effects, adverse events, and regulatory approval timelines.
📋 Key Facts
- Hosted KOL event on May 31, 2025, following ASCO 2025 presentation.
- Reviewed topline Phase 2 (Actuate-1801 Part 3B) data for elraglusib + GnP in first-line mPDAC.
- KOL discussion included experts from Mayo Clinic, Northwestern University, University of Arizona Cancer Center, and Massachusetts General Hospital.
- The company explicitly notes a need for additional capital to finance operations beyond Q2 fiscal year 2025.
Actuate Therapeutics reported positive topline Phase 2 data for elraglusib in combination with GnP for first-line metastatic pancreatic cancer, meeting its primary endpoint of improved median overall survival. However, the filing contains explicit going concern warnings regarding the company's ability to fund operations beyond Q2 2025.
🚩 Red Flags
- Going concern warning: The company explicitly states its financial condition raises substantial doubt as to its ability to continue as a going concern.
- Liquidity risk: Requires additional capital to finance operations beyond Q2 2025; failure to obtain this could terminate development programs.
📋 Key Facts
- Phase 2 (Actuate-1801 Part 3B) trial met its primary endpoint of improved median overall survival (mOS).
- Elraglusib/GnP mOS was 10.1 months vs. 7.2 months for the control arm (HR=0.63; log-rank p=0.01).
- The combination showed a 37% reduction in the risk of death compared to GnP alone.
- 12-month overall survival rate was 44.1% for elraglusib/GnP vs. 22.3% for the control arm (p=0.0005).
- The trial met its primary safety endpoint with a favorable risk-benefit profile; most adverse events were Grade 1-2.
- Company stated it requires additional capital to finance operations beyond the second quarter of fiscal year 2025.
Actuate Therapeutics, Inc. held its Annual Meeting of Stockholders on May 22, 2025. The meeting resulted in the election of three directors to three-year terms and the ratification of Crowe LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders was held virtually on May 22, 2025.
- Dr. Roger Sawhney elected to the Board (14,216,991 votes for).
- Mr. Todd Thomson elected to the Board (14,058,447 votes for).
- Dr. Dan Zabrowski elected to the Board (14,009,434 votes for).
- Crowe LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- All directors were elected to terms lasting until the 2028 Annual Meeting.
Actuate Therapeutics announced positive topline data from its Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma. While clinical results are positive, the company's cautionary language explicitly notes substantial doubt regarding its ability to continue as a going concern without significant additional capital.
🚩 Red Flags
- Going concern warning: The company's financial condition raises 'substantial doubt' regarding its ability to continue as a going concern.
- Liquidity crisis: Management anticipates needing substantial additional capital after the second quarter of fiscal year 2025.
- Clinical risk: Preliminary and unpublished data is subject to change upon further review.
📋 Key Facts
- Announced positive topline data from Actuate-1801 Part 3B (Phase 2 trial).
- Trial evaluated elraglusib + gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
- The Phase 2 trial is described as ongoing and fully enrolled.
- Company explicitly states it will require substantial additional capital to finance operations beyond Q2 fiscal year 2025.
Actuate Therapeutics entered into a Common Stock Purchase Agreement and Registration Rights Agreement with B. Riley Principal Capital II, providing the company the right to sell up to $50 million of newly issued common stock over 36 months.
🚩 Red Flags
- Equity Dilution: The agreement allows for significant dilution through the issuance of up to $50M in new shares.
- Variable Pricing/Discount: Shares are sold at a 3.0% discount to VWAP, which can create downward pressure on the stock price.
- Restrictive Covenants: Prohibits the company from entering into other 'Variable Rate Transactions' (e.g., equity lines of credit) during the term.
📋 Key Facts
- Total potential equity offering: Up to $50,000,000 in common stock.
- Counterparty: B. Riley Principal Capital II, LLC.
- Structure: Includes 'Market Open Purchases' and 'Intraday Purchases' at a 3.0% discount to VWAP.
- Term: Up to 36 months from the Commencement Date.
- Pricing: Determined by volume-weighted average price (VWAP) minus a 3.0% discount.
- Use of proceeds: Working capital and general corporate purposes.
Actuate Therapeutics announced the date for its first Annual Meeting of Stockholders, scheduled to be held virtually on May 22, 2025. The filing also establishes record dates and deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: May 22, 2025 (Virtual).
- Record Date for voting rights: March 25, 2025.
- Deadline for Rule 14a-8 stockholder proposals: February 21, 2025.
- Advance notice deadline for director nominations and other non-Rule 14a-8 proposals: February 21, 2025.
Actuate Therapeutics announced positive interim data from its Phase 2 trial (Actuate-1801 Part 3B) evaluating elraglusib in combination with gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma. The company also updated its investor presentation to reflect these findings.
🚩 Red Flags
- Clinical trial outcomes are inherently uncertain; preliminary/unpublished data may be subject to change.
📋 Key Facts
- Released positive interim data from a fully enrolled randomized Phase 2 trial (Actuate-1801 Part 3B).
- The trial evaluates elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
- Updated the investor presentation on the company's website to include the interim data.
- Data is considered preliminary and subject to change following more comprehensive review.
Actuate Therapeutics, Inc. announced that the FDA has granted Rare Pediatric Disease Designation for its product candidate elraglusib to treat Ewing sarcoma.
📋 Key Facts
- FDA granted Rare Pediatric Disease Designation for elraglusib.
- Target indication: treatment of Ewing sarcoma.
- Filing date: November 12, 2024.
Actuate Therapeutics, Inc. has replaced its independent auditor, KMJ Corbin & Company LLP, with Crowe LLP effective August 19, 2024. The filing notes that the previous auditor's reports included a going concern warning and that the company previously reported material weaknesses in internal controls.
🚩 Red Flags
- Going concern language present in the two most recently completed fiscal years (2022 and 2023).
- Auditor change occurring alongside a history of material weaknesses in internal controls over financial reporting.
- Previous issues with improper accruals of clinical trial expenses.
📋 Key Facts
- KMJ Corbin & Company LLP resigned as the independent registered public accounting firm on August 19, 2024.
- Crowe LLP has been appointed to serve as the new independent auditor for the fiscal year ending December 31, 2024.
- The company's audit reports for fiscal years 2022 and 2023 included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- A material weakness in internal control over financial reporting was previously reported due to inadequate review of clinical trial expense accruals.
- The company stated there were no disagreements with KMJ regarding accounting principles or auditing procedures prior to resignation.
Actuate Therapeutics, Inc. successfully completed its initial public offering (IPO) of 2,800,000 shares at $8.00 per share, raising approximately $19.2 million in net proceeds. The filing also details significant corporate governance changes and amendments to the company's charter following the IPO.
🚩 Red Flags
- Implementation of a classified board (staggered terms), which can make it more difficult for activist investors to change the board.
- Provisions requiring a two-thirds majority vote for director removal 'for cause' and eliminating stockholder action by written consent, both of which are anti-takeover measures.
📋 Key Facts
- Completed IPO of 2,800,000 shares at $8.00 per share on August 14, 2024.
- Net proceeds from the IPO totaled $19.2 million after expenses and discounts.
- Underwriters granted an option to purchase up to 420,000 additional shares for over-allotments.
- Appointed three independent directors: Jason Keyes, Roger Sawhney, and Amy Ronneberg.
- Les Kreis, Jr. resigned from the Board effective prior to the IPO closing.
- Amended Certificate of Incorporation increases authorized common stock to 200,000,000 shares and authorizes 10,000,000 shares of preferred stock.